{'fraction_non_alphanumeric': 0.021897810218978103, 'fraction_numerical': 0.0, 'mean_word_length': 5.260273972602739, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ovarian cancer investigators aim at cell signaling pathways.

HOUSTON—Identification of the cellular and genetic abnormalities involved in all types of cancer is providing new therapeutic avenues for researchers to pursue. Efforts to translate this knowledge into innovative therapies for ovarian cancer took the spotlight at the first International Conference on Ovarian Cancer, held at the University of Texas last month. Ovarian cancer, which has the highest mortality rate of all gynecologic cancers and is the fourth leading cause of cancer deaths among women in the United States, can usually be treated and cured if caught early. But all too often, it causes only vague symptoms that go unnoticed until the tumor is advanced and the prognosis is poor. To discuss the latest advances in treatment of the disease, several hundred gynecologic oncologists, medical oncologists, radiologists, other physicians, and oncology nurses from around the world attended the conference, which was cosponsored by M. D. Anderson Cancer Center here and Memorial SloanKettering Cancer Center in New York City. Gordon Mills, MD, PhD, chair of M.D. Anderson’s molecular oncology department, told the group, “The most important challenge we face over the next decade is to take the incredible understanding of cancer that we now have and start translating this intopatientmanagement.”